CORONA Remedies Commences Production at Advanced EU-GMP Women's Hormone Facility
CORONA Remedies has commenced commercial production at its new EU-GMP approved Women's Hormone manufacturing facility in Bhayla, Ahmedabad. The facility has an annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels, increasing the company's in-house hormone manufacturing capacity by nearly 20%. The facility aims to serve both domestic and international markets.
The new facility increases manufacturing capacity and strengthens the company's position in a specialized pharmaceutical segment, which could lead to increased revenue and market share. However, the full impact will depend on market adoption and sales performance.
The commencement of a new, advanced manufacturing facility, especially one focused on a critical area like women's healthcare and meeting high regulatory standards (EU-GMP), is a positive development for the company.
CORONA Remedies Limited has inaugurated and commenced commercial production at its EU-GMP approved Women’s Hormone manufacturing facility located in Bhayla, Ahmedabad. This state-of-the-art facility, inaugurated on June 30, 2026, by Chairman Dr. K. L. Mehta and long-serving women employees, signifies a major step in the company's aim to build globally benchmarked pharmaceutical manufacturing capabilities.
The facility is designed to address the growing global demand for specialized, high-quality pharmaceutical manufacturing for women's healthcare, driven by increasing awareness and diagnosis of hormonal disorders, fertility care, menopause management, and hormone replacement therapies. Hormonal medicines are complex to manufacture, requiring dedicated facilities with sophisticated technologies and stringent containment controls.
CORONA's integrated manufacturing platform supports multiple dosage forms including tablets, soft gel capsules, ointments, and gels. Spread across 1.0 lakh sq. ft., the facility has an annual manufacturing capacity of 194 million tablets/capsules and 1.5 million ointments/gels. The commissioning of this facility is expected to increase CORONA's in-house hormone manufacturing capacity by approximately 20%. The facility incorporates advanced technologies such as fully integrated closed-loop manufacturing systems, advanced gelatin processing systems, and real-time online process monitoring.
Mr. Nirav K. Mehta, Founder, Managing Director & CEO, stated that the dedicated hormone facility represents their commitment to delivering globally benchmarked quality, strengthening India's pharmaceutical manufacturing ecosystem, and ensuring women have access to safe, reliable, and high-quality hormone therapies.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.